Free Trial

Theratechnologies (NASDAQ:THTX) Issues Quarterly Earnings Results

Theratechnologies logo with Medical background

Theratechnologies (NASDAQ:THTX - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.08), Zacks reports. The firm had revenue of $17,729 billion during the quarter, compared to the consensus estimate of $24.30 million.

Theratechnologies Stock Performance

Shares of THTX remained flat at $3.15 during mid-day trading on Friday. The stock had a trading volume of 463,861 shares, compared to its average volume of 895,666. The stock has a market capitalization of $144.84 million, a P/E ratio of -16.58 and a beta of 0.55. The company's fifty day moving average price is $2.64 and its two-hundred day moving average price is $2.11. Theratechnologies has a one year low of $1.12 and a one year high of $3.20.

Wall Street Analysts Forecast Growth

Separately, Jones Trading lowered Theratechnologies from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 3rd.

Get Our Latest Stock Analysis on THTX

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Theratechnologies stock. Acadian Asset Management LLC bought a new position in Theratechnologies Inc. (NASDAQ:THTX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 28,400 shares of the company's stock, valued at approximately $39,000. Acadian Asset Management LLC owned 0.06% of Theratechnologies at the end of the most recent reporting period.

Theratechnologies Company Profile

(Get Free Report)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

See Also

Earnings History for Theratechnologies (NASDAQ:THTX)

Should You Invest $1,000 in Theratechnologies Right Now?

Before you consider Theratechnologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.

While Theratechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines